The course titled “Cannabis Therapy from Z to Z: Basics and Practical Use of Cannabis Drugs in Medical Practice and Pharmacy” is a comprehensive, practice-oriented, interdisciplinary certificate course for physicians, providing in-depth knowledge of all aspects. of cannabis therapy, which physicians and pharmacists need for the appropriate and responsible therapeutic use of all cannabis-based drugs currently available on prescription. At the end of the course, advanced training points are awarded by the
The course program is developed, led and taught by three leading scientific and clinical experts in cannabis medicine: Dr Franjo Grotenhermen, Dr.
Dr Franjo Grotenhermen is a world renowned leader and expert in the therapeutic use of cannabinoids. He is the chairman of
Dr.
Dr.
âAs the cannabis space continues to evolve, there will be an ongoing need for education, training and pedagogy for physicians and practitioners that is not only engaging and flexible, but also highly sophisticated. The blended learning approach of our course combines self-learning and intensive face-to-face and online group work, to incubate ideal conditions for the acquisition and application of skills. Telaleaf believes that proper medical education improves treatment and the patient experience. The success of cannabis medicine begins with educational models that bridge the gap between theoretical and practical application to raise the clinical standard among physicians for the appropriate therapeutic use of cannabis products.
LGP Operations Director,
The first certificate course starts
About Telaleaf
Telaleaf is a telemedicine company that is revolutionizing the delivery of cannabis-related care by connecting patients with expert physicians, trained in cannabis-based medicine,
On
For more information please contact:
Email: [email protected]
Phone: 1-647-493-8641
Contact details:
telefeuille
Contact by e-mail
www.telaleaf.com
Read the full article here: https://www.pr.com/press-release/845119
Press release distributed by PR.com
Copyright © 2021 PR.com and its licensors, source